Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 4/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5967397 | 0.83 | — | — | |
| SCHEMBL6270743 | 0.83 | — | — | |
| SCHEMBL17729142 | 0.80 | CYP2D6 (0.46) | — | |
| SCHEMBL13278433 | 0.79 | CYP2C9 (0.44) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| SCHEMBL3509472 | 0.79 | CYP2C9 (0.47) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| Cyclohexane SCHEMBL6631080 | 0.78 | CYP2C9 (0.50) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| Cyclohexane SCHEMBL16341926 | 0.78 | CYP2C9 (0.50) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| SCHEMBL13711836 | 0.78 | CYP2C9 (0.50) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| SCHEMBL506450 | 0.78 | CYP2C9 (0.50) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| Cyclohexane SCHEMBL253223 | 0.78 | CYP2C9 (0.50) | CPN1CPB2CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-3452029-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | Bristol-Myers Squibb Company (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192840-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2011146371-A1 | DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CPN1 1107/4885CPB2 720/4885CYP2C9 2175/4885 |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | CPN1 1107/4885CPB2 720/4885CYP2C9 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.